RAD51C and prostate carcinoma: The screening for these mutations in the 710 healthy controls and in the 504 non-prostate cancer cases, as described above, showed absence of the mutations in the control samples and association of the RAD51C mutation c.890_899del with non-prostate cancer development in two patients and of the FANCD2 mutation c.2494+2T>C in one.